USA flag logo/image

An Official Website of the United States Government

Rapid detection of methylglyoxal in blood samples

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43DK095653
Solicitation Year:
2013
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA12-088
Small Business Information
BIOO Scientific
7050 Burleson Rd. Austin, TX 78744-3202
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Rapid detection of methylglyoxal in blood samples
Agency: HHS
Contract: 1R43DK095653-01A1
Award Amount: $161,703.00
 

Abstract:

DESCRIPTION (provided by applicant): Diabetes is a serious, life-threatening disease caused by improper absorption and metabolism of glucose. Increased glucose levels can lead to an accumulation of toxic sugar degradation products, such as methylglyoxal (MG), in the bloodstream. MG is a reactive molecule which can modify and inactivate blood proteins which in turn leads to hypertension, neuropathy, and heart disease. Consequently, MG has been shown to be an excellent biomarker for a number of diabetes-related complications. Unfortunately, all current methods to directly measure MG levels in blood are very expensive, time-consuming and laborious. To fully realize the diagnostic potential of MG, rapid analytical methods are needed for the routine determinationof MG in biomedical samples such as blood. Our proposed Phase I research will create a unique test to measure MG levels in blood samples such as plasma and serum. This unique test will permit researchers to conveniently study the accumulation of reactiveMG in blood before damage to proteins and vasculature has occurred. Our novel assay will use a recombinant bacterial oxidoreductase enzyme (MG-R) capable of specifically and rapidly converting MG into a detectable colorimetric signal in a 96 well plate assay format. To boost sensitivity, we will link our enzymatic detection reaction to an NADP+/NADPH visible colorimetric amplification loop to increase assay sensitivity more than 100-fold. The assay will be optimized and validated using rat and mouse plasmaand serum spiked with known amounts of MG. After validation, we will commercially launch a rapid test kit to directly detect MG in preclinical and other biomedical samples. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Diabetes is a major health threat in the US; this life-threatening disease is rapidly spreading throughout our country (23 million Americans currently affected). Recently, scientists have discovered that a sugar metabolite called methylglyoxal plays a central role in the progression of diabetes - unfortunately there are no methods currently available for routine analysis of methylglyoxal. Our research will create a unique method to rapidly measure methylglyoxal levels in normal and diabetic blood samples; our new analytical method will provide researchers with a critical new diagnostic tool to more-effectively combat diabetes and associated cardiovascular disease.

Principal Investigator:

Joseph F. Krebs
512-651-0200
jkrebs@biooscientific.com

Business Contact:

Joseph Krebs
512-707-8993
jkrebs@biooscientific.com
Small Business Information at Submission:

BIOO SCIENTIFIC CORPORATION
7050 Burleson Road AUSTIN, TX 78744-

EIN/Tax ID: 187078169
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No